mTOR, translational control and human disease

Seminars in Cell and Developmental Biology

Volumn 16, Issue 1, 2005, Pages 29-37

  Tee, Andrew R ^a,b   Blenis, John ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

4E BP1; mTOR; Rapamycin; S6K1; TSC

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; ENZYME INHIBITOR; GENE PRODUCT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR; INITIATION FACTOR 2; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; RAPAMYCIN; S6 KINASE; TARGET OF RAPAMYCIN KINASE; TUBERIN;

ANGIOGENESIS; BENIGN TUMOR; BINDING AFFINITY; BIOGENESIS; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CONGENITAL TUMOR; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; MITOGENESIS; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; TRANSLATION REGULATION; TUBEROUS SCLEROSIS;

MAMMALIA;

EID: 12344262762     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2004.11.005     Document Type: Article

References (89)

1. S.N. Sehgal Sirolimus: its discovery, biological properties, and mechanism of action Transplant Proc 35 2003 7S 14S
2. J.J. Siekierka, S.H. Hung, M. Poe, C.S. Lin, and N.H. Sigal A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin Nature 341 1989 755 777
3. J.J. Siekierka, G. Wiederrecht, H. Greulich, D. Boulton, S.H. Hung, and J. Cryan The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase J. Biol. Chem. 265 1990 21011 21015
4. J. Heitman, N.R. Movva, and M.N. Hall Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast Science 253 1991 905 909
5. R. Bosotti, A. Isacchi, and E.L. Sonnhammer FAT: a novel domain in PIK-related kinases Trends Biochem Sci 25 2000 225 227
6. A. Lorberg, and M.N. Hall TOR: the first 10 years Curr Top Microbiol Immunol 279 2004 1 18
7. D.H. Kim, D.D. Sarbassov, S.M. Ali, J.E. King, R.R. Latek, and H. Erdjument-Bromage mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery Cell 110 2002 163 175
8. D.M. Sabatini, R.K. Barrow, S. Blackshaw, P.E. Burnett, M.M. Lai, and M.E. Field Interaction of RAFT1 with gephyrin required for rapamycin-sensitive signalling Science 284 1999 1161 1164
9. K. Hara, Y. Maruki, X. Long, K. Yoshino, N. Oshiro, and S. Hidayat Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action Cell 110 2002 177 189
10. D.H. Kim, D.D. Sarbassov, S.M. Ali, R.R. Latek, K.V. Guntur, and H. Erdjument-Bromage GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR Mol Cell 11 2003 895 904
11. R. Loewith, E. Jacinto, S. Wullschleger, A. Lorberg, J.L. Crespo, and D. Bonenfant Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control Mol Cell 10 2002 457 468
12. D.D. Sarbassov, S.M. Ali, D.H. Kim, D.A. Guertin, R.R. Latek, and H. Erdjument-Bromage Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton Curr Biol 14 2004 1296 1302
13. T. Powers, I. Dilova, C.Y. Chen, and K. Wedaman Yeast TOR signaling: a mechanism for metabolic regulation Curr Top Microbiol Immunol 279 2004 39 51
14. D.C. Fingar, and J. Blenis Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression Oncogene 23 2004 3151 3171
15. J.C. Anthony, F. Yoshizawa, T.G. Anthony, T.C. Vary, L.S. Jefferson, and S.R. Kimball Leucine stimulates translation initiation in skeletal muscle of postabsorptive rats via a rapamycin-sensitive pathway J Nutr 130 2000 2413 2419
16. C.J. Richardson, S.S. Schalm, and J. Blenis PI3-kinase and TOR: PIKTORing cell growth Semin Cell Dev Biol 15 2004 147 159
17. C. Tokunaga, K. Yoshino, and K. Yonezawa mTOR integrates amino acid- and energy-sensing pathways Biochem Biophys Res Commun 313 2004 443 446
18. P.B. Dennis, A. Jaeschke, M. Saitoh, B. Fowler, S.C. Kozma, and G. Thomas Mammalian TOR: a homeostatic ATP sensor Science 294 2001 1102 1105
19. A.C. Gingras, B. Raught, and N. Sonenberg Regulation of translation initiation by FRAP/mTOR Genes Dev 15 2001 807 826
20. K.A. Martin, and J. Blenis Coordinate regulation of translation by the PI 3-kinase and mTOR pathways Adv Cancer Res 86 2002 1 39
21. G.J. Browne, and C.G. Proud Regulation of peptide-chain elongation in mammalian cells Eur J Biochem 269 2002 5360 5368
22. A.C. Gingras, B. Raught, S.P. Gygi, A. Niedzwiecka, M. Miron, and S.K. Burley Hierarchical phosphorylation of the translation inhibitor 4E-BP1 Genes Dev 15 2001 2852 2864
23. G.J. Brunn, P. Fadden, T.A. Haystead, and J.C. Lawrence Jr. The mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus J Biol Chem 272 1997 32547 32550
24. A.C. Gingras, S.P. Gygi, B. Raught, R.D. Polakiewicz, R.T. Abraham, and M.F. Hoekstra Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism Genes Dev 13 1999 1422 1437
25. H. Nojima, C. Tokunaga, S. Eguchi, N. Oshiro, S. Hidayat, and K. Yoshino The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif J Biol Chem 278 2003 15461 15464
26. S.S. Schalm, D.C. Fingar, D.M. Sabatini, and J. Blenis TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function Curr Biol 13 2003 797 806
27. K.M. Choi, L.P. McMahon, and J.C. Lawrence Jr. Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor J Biol Chem 278 2003 19667 19673
28. S.S. Schalm, and J. Blenis Identification of a conserved motif required for mTOR signalling Curr Biol 12 2002 632 639
29. D. Rousseau, A.C. Gingras, A. Pause, and N. Sonenberg The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth Oncogene 13 1996 2415 2420
30. M.A. Bjornsti, and P.J. Houghton Lost in translation: dysregulation of cap-dependent translation and cancer Cancer Cell 5 2004 519 523
31. D.C. Fingar, S. Salama, C. Tsou, E. Harlow, and J. Blenis Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E Genes Dev 16 2002 1472 1487
32. D.C. Fingar, C.J. Richardson, A.R. Tee, L. Cheatham, C. Tsou, and J. Blenis mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E Mol Cell Biol 24 2004 200 216
33. D.R. Alessi, M.T. Kozlowski, Q.P. Weng, N. Morrice, and J. Avruch 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro Curr Biol 8 1998 69 81
34. J. Chung, C.J. Kuo, G.R. Crabtree, and J. Blenis Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases Cell 69 1992 1227 1236
35. R.S. Westphal, R.L. Coffee Jr., A. Marotta, S.L. Pelech, and B.E. Wadzinski Identification of kinase-phosphatase signaling modules composed of p70 S6 kinase-protein phosphatase 2A (PP2A) and p21-activated kinase-PP2A J Biol Chem 274 1999 687 692
36. R.T. Peterson, B.N. Desai, J.S. Hardwick, and S.L. Schreiber Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein Proc Natl Acad Sci USA 96 1999 4438 4442
37. C.J. Richardson, M. Broenstrup, D.C. Fingar, K. Jülich, B.A. Ballif, and S.P. Gygi SKAR is a specific target of S6 kinase 1 in cell growth control Curr Biol 14 2004 1540 1549
38. H.B. Jefferies, S. Fumagalli, P.B. Dennis, C. Reinhard, R.B. Pearson, and G. Thomas Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k EMBO J. 16 1997 3693 3704
39. H. Tang, E. Hornstein, M. Stolovich, G. Levy, M. Livingstone, and D. Templeton Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation Mol Cell Biol 21 2001 8671 8683
40. M. Pende, S.H. Um, V. Mieulet, M. Sticker, V.L. Goss, and J. Mestan S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway Mol Cell Biol 24 2004 3112 3124
41. A. Grolleau, J. Bowman, B. Pradet-Balade, E. Puravs, S. Hanash, and J.A. Garcia-Sanz Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics J Biol Chem 277 2002 22175 22184
42. X. Wang, W. Li, M. Williams, N. Terada, D.R. Alessi, and C.G. Proud Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase EMBO J 20 2001 4370 4379
43. A. Knebel, N. Morrice, and P. Cohen A novel method to identify protein kinase substrates: eEF2 kinase is phosphorylated and inhibited by SAPK4/p38delta EMBO J 20 16 2001 4360 4369
44. G.J. Browne, and C.G. Proud A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin Mol Cell Biol 24 2004 2986 2997
45. B.D. Manning, and L.C. Cantley Rheb fills a GAP between TSC and TOR Trends Biochem Sci 28 2003 573 576
46. J.P. Cheadle, M.P. Reeve, J.R. Sampson, and D.J. Kwiakowski Molecular genetic advances in tuberous sclerosis Hum Genet 107 2000 97 114
47. X. Gao, and D. Pan TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth Genes Dev 15 2001 1383 1392
48. E.J. McManus, and D.R. Alessi TSC1-TSC2: a complex tale of PKB-mediated S6K regulation Nat Cell Biol 4 2002 214 216
49. K. Inoki, Y. Li, T. Zhu, J. Wu, and K.L. Guan TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling Nat Cell Biol 4 2002 648 657
50. A.R. Tee, D.C. Fingar, B.D. Manning, D.J. Kwiatkowski, L.C. Cantley, and J. Blenis Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signalling Proc Natl Acad Sci USA 99 2002 13571 13576
51. Y. Niida, N. Lawrence-Smith, A. Banwell, E. Hammer, J. Lewis, and R.L. Beauchamp Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis Hum Mutat 14 1999 412 422
52. K.E. Mach, K.A. Furge, and C.F. Albright Loss of Rhb1, a Rheb-related GTPase in fission yeast, causes growth arrest with a terminal phenotype similar to that caused by nitrogen starvation Genetics 155 2000 611 622
53. J. Urano, A.P. Tabancay, W. Yang, and F. Tamanoi The Saccharomyces cerevisiae Rheb G-protein is involved in regulating canavanine resistance and arginine uptake J Biol Chem 275 2000 11198 11206
54. H. Stocker, T. Radimerski, B. Schindelholz, F. Wittwer, P. Belawat, and P. Daram Rheb is an essential regulator of S6K in controlling cell growth in Drosophila Nat Cell Biol 5 2003 559 565
55. L.J. Saucedo, X. Gao, D.A. Chiarelli, L. Li, D. Pan, and B.A. Edgar Rheb promotes cell growth as a component of the insulin/TOR signalling network Nat Cell Biol 5 2003 566 571
56. Y. Zhang, X. Gao, L.J. Saucedo, B. Ru, B.A. Edgar, and D. Pan Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins Nat Cell Biol 5 2003 578 581
57. A. Garami, F.J. Zwartkruis, T. Nobukuni, M. Joaquin, M. Roccio, and H. Stocker Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2 Mol Cell 11 2003 1457 1466
58. K. Inoki, Y. Li, T. Xu, and K.L. Guan Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signalling Genes Dev 17 2003 1829 1834
59. A.R. Tee, B.D. Manning, P.P. Roux, L.C. Cantley, and J. Blenis Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb Curr Biol 13 2003 1259 1268
60. H.W. Fu, and P.J. Casey Enzymology and biology of CaaX protein prenylation Recent Prog Horm Res 54 1999 315 343
61. A.D. Cox Farnesyltransferase inhibitors: potential role in the treatment of cancer Drugs 61 2001 723 732
62. E.C. Lerner, T.T. Zhang, D.B. Knowles, Y. Qian, A.D. Hamilton, and S.M. Sebti Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines Oncogene 15 1997 1283 1288
63. D.W. End, G. Smets, A.V. Todd, T.L. Applegate, C.J. Fuery, and P. Angibaud Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro Cancer Res 61 2001 131 137
64. A.F. Castro, J.F. Rebhun, G.J. Clark, and L.A. Quilliam Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner J Biol Chem 278 2003 32493 32496
65. B.D. Manning, A.R. Tee, M.N. Logsdon, J. Blenis, and L.C. Cantley Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway Mol Cell 10 2002 151 162
66. G.B. Mills, Y. Lu, and E.C. Kohn Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo Proc Natl Acad Sci USA 98 2001 10031 10033
67. M.S. Neshat, I.K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, and R. Petersen Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci USA 98 2001 10314 10319
68. S. Huang, and P.J. Houghton Targeting mTOR signaling for cancer therapy Curr Opin Pharmacol 3 2003 371 377
69. T.R. Foley, T.J. McGarrity, and A.B. Abt Peutz-Jeghers syndrome: a clinicopathologic survey of the "Harrisburg family" with a 49-year follow-up Gastroenterology 95 1988 1535 1540
70. S.P. Hong, F.C. Leiper, A. Woods, D. Carling, and M. Carlson Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases Proc Natl Acad Sci USA 100 2003 8839 8843
71. A. Woods, S.R. Johnstone, K. Dickerson, F.C. Leiper, L.G. Fryer, and D. Neumann LKB1 is the upstream kinase in the AMP-activated protein kinase cascade Curr Biol 13 2003 2004 2008
72. D.G. Hardie, and D. Carling The AMP-activated protein kinase - fuel gauge of the mammalian cell? Eur J Biochem 246 1997 259 273
73. N. Kimura, C. Tokunaga, S. Dalal, C. Richardson, K. Yoshino, and K. Hara A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway Genes Cells 8 2003 65 79
74. K. Inoki, T. Zhu, and K.L. Guan TSC2 mediates cellular energy response to control cell growth and survival Cell 115 2003 577 590
75. M.N. Corradetti, K. Inoki, N. Bardeesy, R.A. DePinho, and K.L. Guan Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome Genes Dev 18 2004 1533 1538
76. R.J. Shaw, N. Bardeesy, B.D. Manning, L. Lopez, M. Kosmatka, and R.A. DePinho The LKB1 tumor suppressor negatively regulates mTOR signalling Cancer Cell 6 2004 91 99
77. N. El-Hashemite, V. Walker, H. Zhang, and D.J. Kwiatkowski Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin Cancer Res 63 2003 5173 5177
78. M. Guba, P. von Breitenbuch, M. Steinbauer, G. Koehl, S. Flegel, and M. Hornung Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 2002 128 135
79. C.C. Hudson, M. Liu, G.G. Chiang, D.M. Otterness, D.C. Loomis, and F. Kaper Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin Mol Cell Biol 22 2002 7004 7014
80. A. Ylikorkala, D.J. Rossi, N. Korsisaari, K. Luukko, K. Alitalo, and M. Henkemeyer Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice Science 293 2001 1323 1326
81. T. Shioi, J.R. McMullen, P.M. Kang, P.S. Douglas, T. Obata, and T.F. Franke Akt/protein kinase B promotes organ growth in transgenic mice Mol Cell Biol 22 2002 2799 2809
82. T. Shioi, J.R. McMullen, O. Tarnavski, K. Converso, M.C. Sherwood, and W.J. Manning Rapamycin attenuates load-induced cardiac hypertrophy in mice Circulation 107 2003 1664 1670
83. T.C. Woods, and A.R. Marks Drug-eluting stents Annu Rev Med 55 2004 169 178
84. L. Wang, and C.G. Proud Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes Circ Res 91 2002 821 829
85. A.R. Tee, R. Anjum, and J. Blenis Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin J Biol Chem 278 2003 37288 37296
86. A. Shimamura, B.A. Ballif, S.A. Richards, and J. Blenis Rsk1 mediates a MEK-MAP kinase cell survival signal Curr Biol 10 2000 127 135
87. P.P. Roux, B.A. Ballif, R. Anjum, S.P. Gygi, and J. Blenis Tumor promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via RSK PNAS 101 2004 13489 13494
88. R.S. Kandt Tuberous sclerosis complex and neurofibromatosis type 1: the two most common neurocutaneous diseases Neurol Clin 21 November (4) 2003 983 1004
89. K. Cichowski, and T. Jacks NF1 tumor suppressor gene function: narrowing the GAP Cell 104 2001 593 604